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Abstract: The Gastric Cancer (Biomarkers) Knowledgebase (GCBKB) (http://biomarkers.bii.a-star.edu.sg/background/
gastricCancerBiomarkersKb.php)is a curated and fully integrated knowledgebase that provides data relating to putative 
biomarkers that may be used in the diagnosis and prognosis of gastric cancer. It is freely available to all users. The data 
contained in the knowledgebase was derived from a large literature source and the putative biomarkers therein have been 
annotated with data from the public domain. The knowledgebase is maintained by a curation team who update the data from 
a deﬁ  ned source. As well as mining data from the literature, the knowledgebase will also be populated with unpublished 
experimental data from investigators working in the gastric cancer biomarker discovery ﬁ  eld. Users can perform searches 
to identify potential markers deﬁ  ned by experiment type, tissue type and disease state. Search results may be saved, ma-
nipulated and retrieved at a later date. As far as the authors are aware this is the ﬁ  rst open access database dedicated to the 
discovery and investigation of gastric cancer biomarkers.
Introduction
Although the overall incidence of gastric cancer worldwide is decreasing, it is still a major health 
problem and, after lung cancer, it is the second leading cause of cancer death (Hohenberger and Gretschel, 
2003). It has been estimated that there are 876 000 new cases diagnosed and 649 000 deaths reported 
per annum worldwide (Roberts-Thompson and Butler, 2005). Countries of high incidence include 
Singapore, China, Japan and Russia (Look et al. 2001). The overall decrease in the incidence of gastric 
cancer has been attributed to domestic refrigeration, a decrease in the intake of salted, smoked and 
pickled foods and the greater availability and consumption of fresh fruit and vegetables. There are other 
environmental factors, apart from diet, that increase the risk of gastric cancer in susceptible individuals 
including tobacco smoking (Nouraie et al. 2005), alcohol consumption (Leung et al. 2005) and Heli-
cobacter pylori infection (Normark et al. 2003). A two to three fold increase in the risk of gastric cancer 
has been linked to H.pylori infection in some but not all populations (Look et al. 2001). There is epide-
miological evidence of genetic risk factors associated with gastric cancer including higher than predicted 
concordance rates in identical and non-identical twins and ﬁ  rst degree relatives of patients with gastric 
cancer having a two to three fold increased risk of developing the disease (El-Omar et al. 2000).
Gastric carcinoma is characterized by aggressive metastasis. There are a number of molecular factors 
that are thought to contribute to this property including microsatellite instability, activation of oncogenes, 
inactivation of tumor suppressor genes and abnormal activation of telomerase (Wong et al. 2006). These 
factors have an enormous inﬂ  uence on the control of cell growth and differentiation and give rise to 
very resilient gastric cancer cells. The aggressive metastasis and the high resilience of the cancerous 
cells contribute to the very poor survival rates of gastric cancer patients. The 5 year survival rate in 
patients who undergo surgery is less than 40% (Wanebo et al. 1993). However, survival rates are vastly 
improved when gastric cancer is diagnosed early. Studies have shown that up to 80% of patients diag-
nosed with gastric cancer have advanced and incurable stage IV disease and only 1% have early disease 
(Sue-Ling, 1998). To improve the survival rates of this disease, earlier diagnosis is vital. In countries 
such as Japan, where the incidence of the disease is high, mass screening of the population has led to 
higher detection levels of the disease at an earlier stage. However, in other populations, screening of 
high risk individuals is thought to be economically more viable. Those considered to be at risk include 
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patients with symptoms of pernicious anemia, 
gastric ulcer and chronic atrophic gastritis. The main 
form of screening involves the use of the two proce-
dures, endoscopy and biopsy. The invasive nature 
of these two techniques makes routine screening 
for gastric cancer both undesirable for the patient 
and expensive for the health care provider. This has 
provided the impetus for researchers to focus their 
efforts on the discovery of diagnostic biomarkers 
that can be detected in readily accessible body 
ﬂ  uids (for example serum, plasma and urine) for 
the early detection of gastric cancer. 
Biomarkers can be deﬁ  ned as molecules that 
can be measured in a patient’s body ﬂ  uids or tissues 
to diagnose a disease at the molecular level, to 
monitor the response to therapy or predict the 
prognosis for a given disease. In the past twenty 
years less than 12 biomarkers have been approved 
by the FDA for use in cancer diagnosis and therapy 
(Anderson and Anderson, 2002). However, literally 
thousands of putative biomarkers for cancer diag-
nosis and detection have been discovered and 
described in the literature (Manne et al. 2005). The 
generation of this wealth of data has been driven 
by the development of new techniques such as 
DNA microarrays, mass spectroscopy and tissue 
arrays. A not insigniﬁ  cant number of the putative 
cancer biomarkers reported in the literature are 
related to gastric cancer. This data is of great value 
to both scientiﬁ  c researchers and clinicians alike 
who are working in the ﬁ  eld of gastric cancer 
biomarker discovery. In order to facilitate the 
discovery process, a project was initiated to 
construct an integrated user friendly knowledge-
base that catalogues putative markers related to the 
gastric cancer disease process. It is hoped that this 
freely accessible resource will be equally as valu-
able to the experimentalist as it will be to the in 
silico researcher. 
Overview of the Database
The gastric cancer biomarker knowledgebase 
(GCBKB) is a web based resource that contains 
data on putative gene and protein biomarkers that 
have been identiﬁ  ed as being associated with the 
gastric cancer process. The data is derived from 
peer reviewed journals and is updated on a regular 
basis by a curation team. The GCBKB also contains 
data from experimental collaborators working in 
the ﬁ  eld of gastric cancer biomarker discovery. 
Data submitted to the curators of the knowledge-
base will be reviewed by them and a panel of local 
experts. Once an agreement is reached between the 
collators, the experimentalists and the panel, the 
data will be uploaded to the knowledgebase. 
The putative markers that can be found in the 
knowledgebase are annotated by KLEGO. KLEGO 
is a fully automated computational annotation 
pipeline that was developed by the Bioinformatics 
Institute, A-Star, Singapore. It extracts annotation 
data from the UCSC genome browser (Karolchik 
et al. 2003) and the UniProt (Bairoch et al. 2005), 
Gene Ontology (Ashburner et al. 2001), InterPro 
(Mulder et al. 2002), Pfam (Finn et al. 2006), BIND 
(Alfarano et al. 2005), IntAct (Hermjakob et al. 
2004), KEGG (Kanehisa et al. 2004), PDB 
(Berman et al. 2003) and UniGene (Boguski and 
Schuler, 1995) databases. The data is integrated 
and displayed on a standard web browser where 
visualization tools such as the chromosome viewer, 
the gene ontology viewer and the interaction 
viewer are available for users to visualize their data 
in a number of formats. KLEGO is freely available 
to all users and can be found at the following URL:
http://klego.bii.a-star.edu.sg/.
The GCBKB allows users to perform searches 
based on selected criteria and provides the facility 
for them to save their search results. After saving 
sets of data, users are also able to manipulate those 
data sets by performing Boolean type procedures. 
The GCBKB will greatly enhance the analysis of 
putative gastric cancer biomarkers by the scientiﬁ  c 
community.
The technical details of the knowledge base are 
as follows:
Server: Sun Fire V240 running Solaris with 2 
UltraSPARC IIIi processors each rated at 1GHz 
with 2GB of memory.
Web Server: Apache 2.0.58 running mod_
php5.
Database: MySQL 4.1.14 
Data Source
The initial data in the knowledgebase is derived 
from 130 research articles published in 60 peer 
reviewed journals between 1998 and 2005 and 
was purchased from Jubilant Biosys (http://www.
jubilantbiosys.com/index.htm). The putative gene 
and protein biomarkers identiﬁ  ed in those 130 
journals have been annotated using KLEGO. 
Additional data is regularly added to the GCBKB 
from 7 journals:
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•  World Journal of Gastroenterology 
•  Clinical Cancer Research 
•  International Journal of Cancer
•  Oncogene
•  Cancer Research
•  Gastric Cancer
•  Proteomics
There were a number of factors considered when 
the 7 journals were chosen including the journal 
source of the original 130 articles, the wish to 
obtain a balance of oncology, gastrointestinal and 
technology based publications and also the wishes 
of external collaborators. The curation team exam-
ines the 7 journals and, based on a series of selec-
tion criteria, extract articles relevant to gastric 
cancer biomarkers. The selection criteria stipulate 
that the putative biomarker be either a protein, an 
indicator of expression (i.e. an mRNA) or a single 
nucleotide polymorphism. There also has to be a 
demonstrable association between some aspect of 
the gastric cancer disease process and the putative 
marker identiﬁ  ed. The data is considered of sufﬁ  -
cient quality as it has gone through the peer review 
process of the journals in which it was originally 
published. The abstracts to those articles are 
uploaded to the knowledgebase and the putative 
biomarkers identified. The gene and protein 
biomarkers are then annotated using KLEGO. To 
date (October, 2006) there are details of 159 journal 
articles from which 443 putative gene and 85 puta-
tive protein gastric cancer biomarkers have been 
identiﬁ  ed.
Access and Use
Use of the GCBKB is open to all. However, for 
users to securely save their data, a simple registra-
tion procedure must be performed. 
From the home page (Figure. 1a) the user can 
access the search page (Figure. 1b) from where the 
search criteria may be selected. Searches may be 
carried out according to experiment type, compar-
ison of tissue type (healthy versus disease) and 
stage of disease. This allows users to differentiate 
between putative biomarkers that are differentially 
expressed between healthy and cancerous tissue 
and putative biomarkers whose expression levels 
reﬂ  ect disease progression. Further ﬁ  lters may be 
applied to searches for example whether there is 
evidence of mutation or whether the protein has 
been identiﬁ  ed in plasma by the Plasma Proteome 
Project (http://www.bioinformatics.med.umich.
edu/hupo/ppp). Results of searches are presented 
on a results page (Figure. 1c) which shows details 
of publications as well as the experimental details 
selected to perform the search. The page is collaps-
ible/expandable to allow the user to determine how 
much information is displayed at any one time. If 
the PubMed ID is selected, details of the publica-
tion can be viewed with a list of experiments 
described in that publication. The experiment ID 
then allows the user to view details of the particular 
experiment and view a list of the putative 
biomarkers identiﬁ  ed. Individual biomarkers may 
be selected to reveal more information and annota-
tion by KLEGO. All or parts of the search results 
may be saved. 
The results manager can be accessed from the 
experimental data menu which appears on all 
views. It allows users to perform editing functions 
on their saved data sets such as deletion, duplica-
tion and data sharing. Results can be visualised 
using the tools provided by KLEGO which is 
accessed via the KLEGO icon. The experimental 
data menu also contains a link to the results sets 
manipulator (Figure. 1d) which allows users to 
perform Boolean type operations on saved data 
sets. For example common putative biomarkers 
found in two different searches and saved in two 
separate data sets can be identiﬁ  ed. 
To extract meaningful information from data-
sets, they have to be interrogated by search criteria. 
To reﬁ  ne the results obtained and to make them 
more speciﬁ  c, further rounds of searching can be 
performed upon them with ever more stringent 
criteria. Users of the GCBKB are able to perform 
this type of iterative procedure and then perform 
Boolean operations such as union and intersect 
upon the generated search results.
To demonstrate one of the many applications of 
the GCBKB, a theoretical biomarker search is 
outlined. An investigator is interested in studying 
putative biomarkers of gastric cancer identiﬁ  ed by 
transcriptomic analyses. If the database is inter-
rogated using ‘microarray analysis’ as the main 
search criteria (Figure. 2a), a list of 201 genes, that 
show differential expression in gastric cancer, is 
generated. The set of results may be saved and 
entitled ‘microarray’ (Figure. 2b). The investigator 
requires that the putative biomarkers be measured 
in plasma. The database can be interrogated for 
putative biomarkers identified in plasma by 
checking the ‘found in plasma proteome project’ 
box in the section ‘ﬁ  lter by biomarker attributes 
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(KLEGO)’ on the search page. This results in 99 
genes and 25 proteins being identiﬁ  ed and may be 
saved as data set ‘plasma.’ To determine which of 
the 201 genes identiﬁ  ed by microarray have been 
identiﬁ  ed in plasma the ‘manipulate results’ tool 
can be used to identify genes common to both sets 
of saved data by performing an intersection oper-
ation (Fig. 2c). This results in the identiﬁ  cation of 
38 candidate biomarkers genes which may be saved 
as set ‘microarray plasma.’ The investigator then 
wishes to validate the transcriptomic data by 
ﬁ  ltering with the ‘RT-PCR’ experiment type criteria 
to determine which genes with differential expres-
sion have been veriﬁ  ed by RT-PCR (Fig. 2d). The 
investigator is ﬁ  nally presented with 5 putative 
biomarkers whose genes are differentially 
expressed in gastric cancer, whose protein products 
have been identiﬁ  ed in plasma and whose expres-
sion changes have been veriﬁ  ed by RT-PCR. The 
resulting 5 genes (MMP2, CCKBR, TIMP1, 
Figure 1. A screenshot of the GCBKB showing the (a) home page, (b) search page, (c) results page and (d) results set manipulator page. 
(a) (b)
(c) (d)
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DAPK1, CAPN9) are presented to the user in such 
a way that abstracts of publications and details of 
experimental data are readily accessible.
Future Direction
In order to provide a greater coverage of tech-
nology based developments that are pertinent to 
the ﬁ  eld of gastric cancer biomarker discovery, 
the number of source journals (currently standing 
at 7) will be expanded to include journals with 
more proteomic and transcriptomic content. In 
order to overcome any biases that may be gener-
ated in the knowledgebase, due to the selection 
of journals that are curated, work has started on 
the development of a text mining engine which 
will be able to search open access databases, such 
as PubMed, for relevant articles. Identified
publications will be manually curated, as they are 
at present, and the relevant biomarker data 
uploaded to the knowledgebase. This will greatly 
expand the data content of the database with
out greatly increasing the resources required to 
maintain it. 
Figure 2. Schematic view of worked search example showing (a) selection of search criteria, (b) saving of data set, (c) intersect operation 
and (d) ﬁ  nal ﬁ  ltering of data. 
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Over the past few years, the ﬁ  eld of biomarker 
discovery has benefited from a considerable 
increase in expenditure on research and develop-
ment in both the academic and industrial sectors. 
Recent scientiﬁ  c drivers of this trend include the 
sequencing of the human genome, the detailed 
comparisons of diseased versus healthy transcrip-
tomes and the advances made in analyzing the 
complexities of the human proteome. Regulatory 
policy making decisions are also contributing to 
the increased activity; the U.S. FDA has identiﬁ  ed 
biomarkers as crucial components in the Critical 
Path Initiative for drugs and diagnostics (Phillips 
et al. 2006). This federally funded initiative has 
been instigated in an attempt to explain how 
increased research and development expenditure 
by the pharmaceutical industry has not led to an 
increase in new drug and diagnostic products being 
made available to patients. The increase in research 
in the biomarker ﬁ  eld is resulting in the generation 
of ever increasing amounts of data and as a conse-
quence there is a need for more data storage devices 
and data analysis tools. More knowledgebases, 
such as the one described in this article, will be 
generated to catalogue putative biomarkers relevant 
to other diseases. This will result in a large dataset 
of proteins and genes which, with the necessary 
validation, will help researchers diagnose disease, 
predict response to therapy and foresee clinical 
outcomes. This dataset of putative gene and protein 
biomarkers will be dynamic with new members 
being added as more studies are performed. Puta-
tive biomarkers will also be removed from the 
dataset as they are subjected to more stringent 
validation procedures and their value as predictive 
entities decreases. This ever changing amalgam of 
genes and proteins can be thought of as the ‘predic-
tome.’ 
To conclude, the primary objective of this 
project was to generate a knowledgebase that 
would be a valuable tool for all those interested in 
the discovery of gastric cancer biomarkers. Hope-
fully this has been achieved and the GCBKB will 
facilitate the discovery of diagnostic biomarkers 
to enable the early detection of gastric cancer. It 
may also help in the discovery biomarkers that can 
be used to monitor the progression of the disease, 
assess the efﬁ  cacy of treatment and stratify the 
disease into subtypes. This in turn may lead to 
increased survival rates and the advent of more 
personalized treatments for patients. 
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